Ifenprodil is one of the drugs we have been investigating for repurposing as a lead candidate for the treatment of idiopathic pulmonary fibrosis (IPF), acute lung injury (ALI) and chronic cough. It is a generic Sanofi neurological drug developed in the 1970’s and is currently approved for use in South Korea and Japan:
- We first investigated Ifenprodil for idiopathic pulmonary fibrosis (IPF), and it outperformed the world’s two leading treatments for the disease – Boehringer Ingelheim’s Nintedanib and Roche’s Pirfenidone – in a pre-clinical in vivo animal study, reducing fibrosis by 56% with statistical significance.
IPF Study Media Release
- We additionally investigated Ifenprodil in a recent acute cough animal study where it outperformed Merck’s phase 3 drug Gefapixant by 110%.
Acute Cough Study Media Release
- On August 5, 2020, we announced that the first patient had been dosed in the Company’s Phase 2 study of Ifenprodil for IPF and chronic cough.
First Patient Dosed Media Release